These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 18576909)
1. Elevated serum tobramycin concentrations after treatment with tobramycin inhalation in a preterm infant. Abdulhamid I; Wise TL; Andrews S; Biglin K; Lehr VT Pharmacotherapy; 2008 Jul; 28(7):939-44. PubMed ID: 18576909 [TBL] [Abstract][Full Text] [Related]
2. Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report. Santos RP; Awa E; Anbar RD BMC Pediatr; 2007 Mar; 7():11. PubMed ID: 17331261 [TBL] [Abstract][Full Text] [Related]
3. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404 [TBL] [Abstract][Full Text] [Related]
4. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142 [TBL] [Abstract][Full Text] [Related]
5. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. Ahya VN; Doyle AM; Mendez JD; Lipson DA; Christie JD; Blumberg EA; Pochettino A; Nelson L; Bloom RD; Kotloff RM J Heart Lung Transplant; 2005 Jul; 24(7):932-5. PubMed ID: 15982625 [TBL] [Abstract][Full Text] [Related]
6. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. Rosenfeld M; Gibson R; McNamara S; Emerson J; McCoyd KS; Shell R; Borowitz D; Konstan MW; Retsch-Bogart G; Wilmott RW; Burns JL; Vicini P; Montgomery AB; Ramsey B J Pediatr; 2001 Oct; 139(4):572-7. PubMed ID: 11598606 [TBL] [Abstract][Full Text] [Related]
7. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482 [TBL] [Abstract][Full Text] [Related]
8. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Edson RS; Brey RH; McDonald TJ; Terrell CL; McCarthy JT; Thibert JM Mayo Clin Proc; 2004 Sep; 79(9):1185-91. PubMed ID: 15357042 [TBL] [Abstract][Full Text] [Related]
9. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure. Patatanian L Pediatr Infect Dis J; 2006 Mar; 25(3):276-8. PubMed ID: 16511399 [TBL] [Abstract][Full Text] [Related]
10. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods. Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125 [TBL] [Abstract][Full Text] [Related]
11. Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation. Prescrire Int; 2002 Dec; 11(62):177-8. PubMed ID: 12469696 [TBL] [Abstract][Full Text] [Related]
12. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Noah TL; Ivins SS; Abode KA; Stewart PW; Michelson PH; Harris WT; Henry MM; Leigh MW Pediatr Pulmonol; 2010 Mar; 45(3):281-90. PubMed ID: 20146365 [TBL] [Abstract][Full Text] [Related]
13. Nebulized tobramycin in patients with chronic respiratory infections during clinical evolution of Wegener's granulomatosis. Terzano C; Taurino AE; Peona V Eur Rev Med Pharmacol Sci; 2001; 5(4):131-8. PubMed ID: 12067081 [TBL] [Abstract][Full Text] [Related]
14. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Stelmach I; Korzeniewska A; Stelmach W Respiration; 2008; 75(2):178-81. PubMed ID: 17435382 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. Latzin P; Fehling M; Bauernfeind A; Reinhardt D; Kappler M; Griese M J Cyst Fibros; 2008 Mar; 7(2):142-6. PubMed ID: 17766190 [TBL] [Abstract][Full Text] [Related]
16. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. de Hoog M; Mouton JW; Schoemaker RC; Verduin CM; van den Anker JN Clin Pharmacol Ther; 2002 May; 71(5):349-58. PubMed ID: 12011820 [TBL] [Abstract][Full Text] [Related]
17. Vestibulotoxicity in a patient without renal failure after inhaled tobramycin. Kaufman AC; Eliades SJ Am J Otolaryngol; 2019; 40(3):456-458. PubMed ID: 30910434 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542 [TBL] [Abstract][Full Text] [Related]
19. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. Badia JR; Soy D; Adrover M; Ferrer M; Sarasa M; Alarcón A; Codina C; Torres A J Antimicrob Chemother; 2004 Aug; 54(2):508-14. PubMed ID: 15215224 [TBL] [Abstract][Full Text] [Related]